Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cipla
Johnson and Johnson
QuintilesIMS
McKinsey
Accenture
Cerilliant
Merck
Chubb

Generated: May 27, 2018

DrugPatentWatch Database Preview

BELVIQ XR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Belviq Xr patents expire, and what generic alternatives are available?

Belviq Xr is a drug marketed by Eisai Inc and is included in one NDA. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-six patent family members in forty-one countries.

The generic ingredient in BELVIQ XR is lorcaserin hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lorcaserin hydrochloride profile page.
Drug patent expirations by year for BELVIQ XR
Synonyms for BELVIQ XR
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepinium chloride
(1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine hydrochloride
(5R)-7-chloro-5-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(R)-1h-3-benzazepine,8-chloro-2,3,4,5-tetrahydro-1-methyl-,hydrochloride
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride salt
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride
(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride hemihydrate
0QJF08GDPE
846589-98-8
AB0080320
AC-8945
ACT10402
AK142745
AKOS005145786
AN-7508
AOB87116
APD-356
BC224447
BCP9000859
Belviq
Belviq (TN)
CHEBI:65350
CHEMBL2095211
CS-0752
D06613
DTXSID60233650
EX-A1697
FT-0696346
HY-15368
ITIHHRMYZPNGRC-QRPNPIFTSA-N
KS-0000006Z
KS-1439
Lorcaserin (Hydrochloride)
Lorcaserin HCl
Lorcaserin hydrochloride
Lorcaserin hydrochloride (USAN)
Lorcaserin hydrochloride [USAN]
Lorcaserin hydrochloride(APD-356)
Lorqess
MFCD09833667
MolPort-005-942-404
QC-9041
SCHEMBL173899
ST24035516
UNII-0QJF08GDPE
W-5408

US Patents and Regulatory Information for BELVIQ XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for BELVIQ XR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 20 mg ➤ Subscribe 2016-12-13

Non-Orange Book US Patents for BELVIQ XR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,906 5HT.sub.2C receptor modulators ➤ Try a Free Trial
7,704,993 Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases ➤ Try a Free Trial
8,404,675 Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases ➤ Try a Free Trial
9,102,627 Processes for preparing 3-benzazepines ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cerilliant
Mallinckrodt
Baxter
Julphar
US Department of Justice
Citi
Daiichi Sankyo
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.